A molecular subanalysis of the GAstrointestinal INestable cohort evaluated secondary fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab, finding that these fusions may be enriched in MLH1-deficient colorectal cancer with mitogen-activated protein kinase wild-type biology. (ESMO Gastrointestinal Oncology)
Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes
The CRC Digest